Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,774.00-1.79%ETH$2,476.01-3.60%GOLD$4,158.80+0.04%OIL$90.94-0.60%
Smart Investors Daily
SID Premium
EV

NASDAQ · EVO

Evotec SE

Healthcare · Drug Manufacturers - Specialty & Generic

$1.61

Down-$0.04 (-2.48%)

Updated Oct 8, 2026, 10:29 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.08B
P/E ratio
-6.02
Dividend yield
0.00%
52-week range
$1.50 – $3.41
Volume
93.14K
Avg. volume
69.26K

Price performance · EVO

EVO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

EVO closed at $1.61 after 21 trading sessions, down 11.05% for the selected period.

Last close
$1.61
Period change
-11.05%
Period low
$1.53
Period high
$1.81
Daily close
View OHLC price history
EVO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$1.60$1.63$1.58$1.6193.14K
Oct 6, 2026$1.73$1.73$1.605$1.63195.01K
Oct 5, 2026$1.61$1.73$1.61$1.66341.98K
Oct 2, 2026$1.63$1.63$1.5907$1.6052.03K
Oct 1, 2026$1.69$1.70$1.645$1.645119.05K
Sep 30, 2026$1.70$1.7122$1.685$1.71101.61K
Sep 29, 2026$1.60$1.64$1.60$1.6494.94K
Sep 28, 2026$1.56$1.59$1.56$1.59187.83K
Sep 25, 2026$1.54$1.56$1.52$1.5620.62K
Sep 24, 2026$1.52$1.5391$1.51$1.5329.85K
Sep 23, 2026$1.55$1.56$1.53$1.5437.26K
Sep 22, 2026$1.55$1.58$1.53$1.58126.96K
Sep 21, 2026$1.62$1.6286$1.50$1.54685.7K
Sep 18, 2026$1.74$1.75$1.57$1.601.38M
Sep 17, 2026$1.62$1.6799$1.62$1.6721.5K
Sep 16, 2026$1.64$1.65$1.61$1.6324.92K
Sep 15, 2026$1.62$1.6499$1.60$1.63102.17K
Sep 14, 2026$1.68$1.69$1.66$1.6837.7K
Sep 11, 2026$1.73$1.76$1.72$1.7342.52K
Sep 10, 2026$1.77$1.77$1.7383$1.7724K
Sep 9, 2026$1.83$1.83$1.805$1.8143.75K

Latest EVO news

The latest Smart Investors Daily articles mentioning EVO.

Stock researchCompany · Overview

EVO research

Overview

Company profile and research snapshot.

Company profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
EVO recent ratings
DateFirmRatingTarget
Sep 21, 2026BERENBERGHold—
Aug 13, 2026TD COWENHold—
Jul 16, 2026EQUI.TSNeutral—
Jun 30, 2026TD COWENBuy—
Jun 29, 2026TD COWENBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

4BIO Capital leads €40 Million ($45M) seed financing of Aptadir Therapeutics to advance first-in-class demethylating medicines

Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the Cancer Science Institute of Singapore London, United Kingdom, 29 September 2026 – 4BIO Capital,

Yahoo · Sep 29, 2026

Evotec Announces Chief Scientific Officer Transition

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.

Yahoo · Sep 29, 2026

APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES

Giovanni Amabile, Founder and CEO Giovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the C

Yahoo · Sep 24, 2026

Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave

Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By